Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Core Insights - Outlook Therapeutics, Inc. announced an amendment to its existing convertible note with Avondale Capital, LLC, extending the maturity date to December 31, 2026, with no other changes to the terms [2] - The company issued a new non-convertible, unsecured note with Atlas Sciences, LLC, amounting to $18.4 million, expecting to receive $17 million in net proceeds after original issue discount [3] - Proceeds from the new note will be utilized to pay down a portion of the existing note, leaving approximately $10.8 million of principal and interest remaining [3] - The new note carries an interest rate of Prime Rate plus 3%, with a minimum interest rate of 9.5% per annum, and matures on June 16, 2027 [4] Company Overview - Outlook Therapeutics is focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to enhance the standard of care for retinal diseases [5] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for the treatment of wet AMD, with commercial launch initiated in Germany, Austria, and the UK [5] - In the U.S., ONS-5010/LYTENAVA™ is currently investigational and, if approved, would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [6]